| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 38 | 2024 | 331 | 8.470 |
Why?
|
| Pleural Neoplasms | 27 | 2024 | 200 | 7.130 |
Why?
|
| Lung Neoplasms | 50 | 2024 | 2363 | 4.950 |
Why?
|
| Tomography, X-Ray Computed | 52 | 2022 | 2562 | 4.550 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 24 | 2023 | 458 | 2.940 |
Why?
|
| Radiography, Thoracic | 22 | 2021 | 323 | 2.610 |
Why?
|
| Solitary Pulmonary Nodule | 19 | 2015 | 138 | 2.580 |
Why?
|
| Radiographic Image Enhancement | 22 | 2015 | 448 | 2.560 |
Why?
|
| Diagnostic Imaging | 13 | 2024 | 448 | 2.540 |
Why?
|
| Lung | 27 | 2021 | 1359 | 2.370 |
Why?
|
| Algorithms | 28 | 2023 | 1948 | 2.000 |
Why?
|
| Diagnosis, Computer-Assisted | 19 | 2023 | 337 | 1.860 |
Why?
|
| Physics | 3 | 2023 | 21 | 1.710 |
Why?
|
| Image Processing, Computer-Assisted | 20 | 2014 | 1269 | 1.660 |
Why?
|
| Pattern Recognition, Automated | 14 | 2013 | 216 | 1.520 |
Why?
|
| Artificial Intelligence | 15 | 2023 | 393 | 1.320 |
Why?
|
| Subtraction Technique | 8 | 2013 | 125 | 1.280 |
Why?
|
| Radiology | 10 | 2023 | 199 | 1.200 |
Why?
|
| Radiologists | 3 | 2021 | 55 | 1.190 |
Why?
|
| Health Physics | 3 | 2023 | 22 | 1.170 |
Why?
|
| Observer Variation | 17 | 2014 | 570 | 1.150 |
Why?
|
| Neoplasm Staging | 13 | 2022 | 2009 | 1.050 |
Why?
|
| Tumor Burden | 10 | 2016 | 321 | 1.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2019 | 60 | 0.960 |
Why?
|
| Biomedical Research | 4 | 2020 | 432 | 0.910 |
Why?
|
| Databases, Factual | 6 | 2011 | 1004 | 0.870 |
Why?
|
| Humans | 109 | 2024 | 93138 | 0.850 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 3 | 2009 | 18 | 0.810 |
Why?
|
| Image Interpretation, Computer-Assisted | 8 | 2018 | 626 | 0.790 |
Why?
|
| Reproducibility of Results | 28 | 2023 | 2705 | 0.780 |
Why?
|
| Radiology Information Systems | 7 | 2020 | 78 | 0.780 |
Why?
|
| Periodicals as Topic | 3 | 2016 | 166 | 0.770 |
Why?
|
| Lung Diseases | 7 | 2006 | 282 | 0.760 |
Why?
|
| Sensitivity and Specificity | 26 | 2015 | 1910 | 0.760 |
Why?
|
| Aged, 80 and over | 28 | 2019 | 7039 | 0.720 |
Why?
|
| Radionuclide Imaging | 5 | 2018 | 180 | 0.700 |
Why?
|
| Tomography, Spiral Computed | 4 | 2005 | 75 | 0.670 |
Why?
|
| Computer-Assisted Instruction | 1 | 2020 | 45 | 0.620 |
Why?
|
| Aged | 39 | 2019 | 20399 | 0.580 |
Why?
|
| Databases as Topic | 7 | 2007 | 96 | 0.580 |
Why?
|
| Pleura | 1 | 2018 | 30 | 0.570 |
Why?
|
| Publications | 1 | 2018 | 32 | 0.530 |
Why?
|
| Societies, Scientific | 1 | 2018 | 40 | 0.530 |
Why?
|
| Middle Aged | 41 | 2023 | 27540 | 0.520 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1098 | 0.510 |
Why?
|
| Image Enhancement | 4 | 2008 | 498 | 0.510 |
Why?
|
| Medicine | 1 | 2018 | 93 | 0.500 |
Why?
|
| Public Opinion | 3 | 2022 | 50 | 0.500 |
Why?
|
| Male | 46 | 2023 | 44357 | 0.500 |
Why?
|
| Female | 48 | 2023 | 48544 | 0.490 |
Why?
|
| Professional Competence | 4 | 2013 | 65 | 0.480 |
Why?
|
| ROC Curve | 13 | 2015 | 774 | 0.470 |
Why?
|
| Mass Screening | 6 | 2023 | 706 | 0.430 |
Why?
|
| Early Detection of Cancer | 5 | 2023 | 504 | 0.430 |
Why?
|
| Tomography, Emission-Computed | 2 | 2016 | 104 | 0.380 |
Why?
|
| Access to Information | 1 | 2013 | 29 | 0.380 |
Why?
|
| Positron-Emission Tomography | 4 | 2022 | 347 | 0.370 |
Why?
|
| Editorial Policies | 1 | 2013 | 33 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 2543 | 0.360 |
Why?
|
| Radiography | 5 | 2023 | 750 | 0.350 |
Why?
|
| Risk Assessment | 1 | 2019 | 2434 | 0.340 |
Why?
|
| Software | 5 | 2013 | 669 | 0.330 |
Why?
|
| Artifacts | 2 | 2009 | 241 | 0.310 |
Why?
|
| Retrospective Studies | 19 | 2019 | 10132 | 0.310 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 396 | 0.300 |
Why?
|
| Thorax | 2 | 2020 | 77 | 0.290 |
Why?
|
| Adult | 28 | 2019 | 27850 | 0.290 |
Why?
|
| Reference Standards | 5 | 2013 | 145 | 0.280 |
Why?
|
| Thoracic Diseases | 1 | 2008 | 28 | 0.270 |
Why?
|
| Survival Rate | 5 | 2019 | 1945 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 4 | 2017 | 226 | 0.270 |
Why?
|
| Forecasting | 1 | 2008 | 288 | 0.260 |
Why?
|
| Congresses as Topic | 2 | 2018 | 120 | 0.250 |
Why?
|
| Cluster Analysis | 4 | 2005 | 391 | 0.250 |
Why?
|
| False Positive Reactions | 7 | 2009 | 212 | 0.250 |
Why?
|
| Mass Chest X-Ray | 1 | 2006 | 5 | 0.240 |
Why?
|
| Peritoneal Neoplasms | 2 | 2022 | 183 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 3450 | 0.240 |
Why?
|
| Quality Control | 5 | 2013 | 123 | 0.240 |
Why?
|
| Radiation Pneumonitis | 2 | 2017 | 23 | 0.240 |
Why?
|
| Contrast Media | 1 | 2011 | 986 | 0.240 |
Why?
|
| Intestines | 1 | 2009 | 433 | 0.230 |
Why?
|
| Machine Learning | 3 | 2023 | 346 | 0.230 |
Why?
|
| Treatment Outcome | 7 | 2019 | 9074 | 0.220 |
Why?
|
| United States | 8 | 2022 | 7581 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 7 | 2017 | 606 | 0.220 |
Why?
|
| Publishing | 1 | 2016 | 91 | 0.220 |
Why?
|
| Phantoms, Imaging | 3 | 2018 | 479 | 0.210 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 214 | 0.210 |
Why?
|
| Rhinitis | 2 | 2017 | 183 | 0.210 |
Why?
|
| Sinusitis | 2 | 2017 | 212 | 0.200 |
Why?
|
| Emphysema | 1 | 2023 | 24 | 0.190 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 43 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 3815 | 0.180 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2015 | 297 | 0.180 |
Why?
|
| Prognosis | 4 | 2018 | 3891 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 103 | 0.160 |
Why?
|
| Information Storage and Retrieval | 3 | 2006 | 125 | 0.160 |
Why?
|
| Systematized Nomenclature of Medicine | 1 | 2020 | 2 | 0.160 |
Why?
|
| Health | 1 | 2020 | 27 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 505 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1055 | 0.160 |
Why?
|
| Angiography | 2 | 2014 | 192 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1519 | 0.150 |
Why?
|
| Data Collection | 2 | 2013 | 370 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 108 | 0.140 |
Why?
|
| Health Resources | 1 | 2019 | 78 | 0.140 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 139 | 0.140 |
Why?
|
| International Cooperation | 1 | 2018 | 132 | 0.140 |
Why?
|
| Ribs | 1 | 1998 | 48 | 0.140 |
Why?
|
| Risk | 1 | 2019 | 651 | 0.140 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 66 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 3155 | 0.130 |
Why?
|
| Automation | 3 | 2006 | 106 | 0.130 |
Why?
|
| Diaphragm | 1 | 1998 | 75 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 2301 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2022 | 810 | 0.130 |
Why?
|
| Illinois | 1 | 2019 | 515 | 0.130 |
Why?
|
| Paranasal Sinuses | 1 | 2017 | 60 | 0.130 |
Why?
|
| Lung Volume Measurements | 2 | 2013 | 24 | 0.120 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 41 | 0.120 |
Why?
|
| United Kingdom | 1 | 2016 | 189 | 0.120 |
Why?
|
| Time Factors | 4 | 2009 | 5379 | 0.120 |
Why?
|
| Regression Analysis | 4 | 2015 | 573 | 0.110 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 78 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 873 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2018 | 394 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2012 | 207 | 0.110 |
Why?
|
| Pulmonary Embolism | 1 | 1997 | 226 | 0.100 |
Why?
|
| Radiation Dosage | 4 | 2017 | 224 | 0.100 |
Why?
|
| Biomarkers | 3 | 2021 | 1905 | 0.100 |
Why?
|
| Colonic Polyps | 2 | 2008 | 137 | 0.100 |
Why?
|
| Knowledge Bases | 3 | 2007 | 16 | 0.100 |
Why?
|
| Bias | 1 | 2014 | 136 | 0.100 |
Why?
|
| Cisplatin | 2 | 2012 | 567 | 0.100 |
Why?
|
| Anatomic Landmarks | 1 | 2013 | 30 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2022 | 1074 | 0.100 |
Why?
|
| Diagnostic Errors | 3 | 2002 | 156 | 0.100 |
Why?
|
| Pemetrexed | 1 | 2012 | 75 | 0.090 |
Why?
|
| Glutamates | 1 | 2012 | 84 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2018 | 201 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 145 | 0.090 |
Why?
|
| Disease Progression | 4 | 2019 | 1529 | 0.090 |
Why?
|
| Fractals | 1 | 2012 | 41 | 0.090 |
Why?
|
| Educational Status | 1 | 2013 | 195 | 0.090 |
Why?
|
| Fourier Analysis | 1 | 2012 | 123 | 0.090 |
Why?
|
| Attitude | 1 | 2013 | 130 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 343 | 0.090 |
Why?
|
| Thoracic Neoplasms | 2 | 2019 | 64 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2014 | 333 | 0.090 |
Why?
|
| Guanine | 1 | 2012 | 194 | 0.090 |
Why?
|
| Child | 2 | 2020 | 7273 | 0.090 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 55 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2012 | 268 | 0.080 |
Why?
|
| Pulmonary Atelectasis | 1 | 2010 | 19 | 0.080 |
Why?
|
| Pneumonia | 1 | 2012 | 192 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 368 | 0.080 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2010 | 62 | 0.080 |
Why?
|
| Models, Theoretical | 2 | 2017 | 494 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2012 | 404 | 0.070 |
Why?
|
| Adolescent | 4 | 2018 | 9550 | 0.070 |
Why?
|
| Xenon Radioisotopes | 2 | 2000 | 9 | 0.070 |
Why?
|
| Ventilation-Perfusion Ratio | 2 | 2000 | 11 | 0.070 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 42 | 0.070 |
Why?
|
| Mammography | 2 | 2023 | 494 | 0.070 |
Why?
|
| Europe | 1 | 2009 | 338 | 0.070 |
Why?
|
| Young Adult | 4 | 2018 | 6922 | 0.070 |
Why?
|
| Chicago | 1 | 2012 | 1452 | 0.070 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2008 | 83 | 0.060 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 90 | 0.060 |
Why?
|
| Photons | 1 | 2006 | 49 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2015 | 336 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2006 | 124 | 0.060 |
Why?
|
| Body Weights and Measures | 1 | 2005 | 25 | 0.060 |
Why?
|
| Consensus | 2 | 2019 | 366 | 0.050 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2004 | 33 | 0.050 |
Why?
|
| Quality of Life | 3 | 2018 | 1776 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1704 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 308 | 0.050 |
Why?
|
| Computers | 1 | 2023 | 102 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2015 | 477 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2017 | 941 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2004 | 194 | 0.050 |
Why?
|
| Remission Induction | 1 | 2005 | 737 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 90 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 80 | 0.050 |
Why?
|
| Patient Care | 1 | 2023 | 97 | 0.050 |
Why?
|
| Ascites | 1 | 2022 | 53 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 304 | 0.040 |
Why?
|
| Mentors | 1 | 2022 | 95 | 0.040 |
Why?
|
| Students | 1 | 2022 | 177 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1130 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 538 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2019 | 71 | 0.040 |
Why?
|
| Physicians | 1 | 2006 | 668 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 66 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 165 | 0.040 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2018 | 20 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2018 | 55 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 425 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1998 | 42 | 0.030 |
Why?
|
| Nurse-Patient Relations | 1 | 2017 | 13 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 298 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 848 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2019 | 217 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1910 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 27965 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 916 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 451 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 401 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 2015 | 193 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2465 | 0.030 |
Why?
|
| Communication | 1 | 2017 | 433 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 4546 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2787 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1719 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 753 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 883 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 561 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1241 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 671 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 205 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3156 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 3781 | 0.020 |
Why?
|
| Research Design | 1 | 2015 | 620 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 254 | 0.020 |
Why?
|
| Education, Medical | 1 | 2013 | 227 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 1171 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2013 | 618 | 0.020 |
Why?
|
| Inflammation | 1 | 2015 | 1049 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 47 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 78 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 70 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1727 | 0.020 |
Why?
|
| Calibration | 1 | 2007 | 107 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2007 | 44 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 391 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 875 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 1000 | 0.010 |
Why?
|
| Motion | 1 | 2006 | 95 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2006 | 99 | 0.010 |
Why?
|
| Fuzzy Logic | 1 | 2005 | 16 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1660 | 0.010 |
Why?
|
| Expert Systems | 1 | 2003 | 18 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 228 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1385 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 1171 | 0.010 |
Why?
|
| Risk Factors | 1 | 2002 | 5901 | 0.010 |
Why?
|